CureVac NV (CVAC)
2.985
+0.10
(+3.65%)
USD |
NASDAQ |
May 09, 16:00
2.985
0.00 (0.00%)
After-Hours: 17:24
CureVac Revenue (TTM): 58.17M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 58.17M |
| September 30, 2023 | 45.82M |
| June 30, 2023 | 39.17M |
| March 31, 2023 | 52.36M |
| December 31, 2022 | 72.06M |
| September 30, 2022 | 107.25M |
| June 30, 2022 | 130.55M |
| March 31, 2022 | 136.08M |
| Date | Value |
|---|---|
| December 31, 2021 | 120.82M |
| September 30, 2021 | 80.87M |
| June 30, 2021 | 52.32M |
| March 31, 2021 | 63.38M |
| December 31, 2020 | 54.73M |
| September 30, 2020 | 55.08M |
| June 30, 2020 | 50.26M |
| March 31, 2020 | 15.79M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
15.79M
Minimum
Mar 2020
136.08M
Maximum
Mar 2022
70.92M
Average
56.62M
Median
Revenue (TTM) Benchmarks
| Affimed NV | 8.941M |
| InflaRx NV | -- |
| MorphoSys AG | 257.99M |
| BioNTech SE | 2.954B |
| Immatics NV | 58.49M |